Healthcare News 26 September 2025

DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

Stock Surges on SteadyMD Acquisition DocGo’s shares jumped more than 34% in after-hours trading on Oct. 20, 2025, after the company announced it would acquire SteadyMD, a virtual care platform. According to an Investing.com report, DocGo stock “surged 34.6% in

21 October 2025

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2%

18 October 2025

Biotechnology · Healthcare · Investment Analysis · NASDAQ:GILD · Pharmaceuticals · Stock Market

INVO Fertility (IVF) Stock’s Wild 90% Surge Amid IVF Boom – What’s Behind the Frenzy?

Stock Price Surge and Aftermath INVO Fertility’s stock took Wall Street by surprise this week with a massive one-day surge. On October 16, shares of the micro-cap fertility clinic operator opened around $0.75 and skyrocketed nearly 90% by day’s end,

17 October 2025

Fertility · Healthcare · Investing · IVF · NASDAQ:INVO · Stock Market

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its

17 October 2025

Healthcare · Industry News · NASDAQ:AKRO · NASDAQ:OMER · NYSE:LLY · NYSE:NVO · Pharmaceuticals · Stock Market · Weight Loss

Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

Lawsuit Outcome and Court Ruling Humana (the second‐largest Medicare Advantage insurer) sued CMS in July after its star rating unexpectedly plunged. The insurer argued that CMS unfairly flagged three interpreter calls as failures (with no callback allowed), causing a 4.5-to-3.5

15 October 2025

Healthcare · Insurance · Legal News · Medicare · NYSE:HUM · Stock Market

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Background: J&J’s Three-Way Split Strategy Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical (Innovative Medicine), and medical technology divisions. In 2023 J&J spun off its consumer products (Tylenol, Band-Aid, Neutrogena, etc.) into a new public company,

14 October 2025

Business News · Corporate Strategy · Healthcare · Industry Trends · Medical Devices · NYSE:JNJ · NYSE:KVUE

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a

6 October 2025

Business News · Healthcare · Investment Trends · NYSE:LLY · NYSE:NVO · NYSE:PFE · Pharma Industry · Stock Market

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Company Overview and Recent Developments Tarsus Pharmaceuticals (NASDAQ: TARS) is a biopharma focused on eye care. Its flagship product XDEMVY (lotilaner ophthalmic solution) was FDA-approved in July 2023 as the first-ever treatment for Demodex blepharitis (eyelid inflammation caused by Demodex mites) globenewswire.com. Tarsus

3 October 2025

Biotechnology · Healthcare · Investment News · NASDAQ:TARS · Pharmaceuticals · Stock Market

Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Stock Performance (Oct 3, 2025) As of midday Oct 3, Humana shares were $272.05, up about +6.01% on the day reuters.com. Yesterday’s close (Oct 2) was $256.62 reuters.com, so HUM has recovered much of last week’s slide. In fact, Oct 1 saw a ~5% drop

3 October 2025

Financial News · Healthcare · Investing · Medicare · NYSE:HUM · Stock Market · Stocks

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

What Is “TrumpRx”? A Direct-to-Consumer Drug Website “TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx will negotiate discounted rates with drugmakers and allow

30 September 2025

Healthcare · NYSE:PFE · Pharmaceuticals · Policy · Politics · US News

European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

Key Facts: Indices Performance European markets closed the first day of the week with small gains. The pan‑European STOXX 600 edged up 0.18% to 555.53 aa.com.tr. Germany’s DAX 40 barely budged (+0.02%) to 23,745.06 aa.com.tr, while Britain’s FTSE 100 added

30 September 2025

Economic Outlook · European Markets · Healthcare · Luxury Goods · NYSE:AZN · NYSE:CCL · NYSE:GSK · Stock Market · Stocks

PACS Group (NYSE:PACS) Pops After NYSE Reprieve—Is the Nursing‑Home Giant Finally Turning the Corner? [Sep 26, 2025]

Key facts (as of Sep 26, 2025) In‑depth report What moved the stock this week PACS rallied into the Sep 26 close with intraday gains reported by market trackers. The surge follows two mid‑September catalysts: (1) NYSE’s listing extension to Nov 19, 2025,

26 September 2025

Healthcare · Investing · Nursing Homes · NYSE · NYSE:PACS · Stock Market

Healthcare News 26 September 2025 - 21 October 2025